Danaher Corporation

Our 2025 Annual Report is now available. Across our portfolio, teams brought together deep scientific expertise, operational excellence, and a strong sense of urgency to help customers turn ideas into impact and address some of the most complex challenges in medicine. Learn more in the report: https://lnkd.in/gqK2_RA8

“Time is the new currency in pathology; from slide preparation to analysis, every moment can influence patient outcomes,” says Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems.   In oncology, faster answers matter. With the launch of Leica Biosystems’ next‑generation digital pathology platform, clinical labs can speed the process of translating images into insights, and physicians can better ensure that patients are getting the right treatments at the right time.    Learn how the new Aperio GT Elite scanner, paired with Aperio iQC software, can help labs move more quickly and see more clearly: https://lnkd.in/eHWeEb8Q

Progress accelerates when expertise connects.   Cytiva’s new partnership with the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) brings together deep expertise across industry and academia to help advance next‑generation medicine platforms.   SR-Tiget, the first non-profit to bring a gene therapy to market in the US, is known for its leadership in making breakthrough advanced therapies more sustainable and accessible to patients—a mission that strongly aligns with our shared focus on acceleration and scalability.   Part of the Danaher Beacons program, this effort is designed to accelerate translation, scalability, and reliability across cell and gene therapy workflows, supporting innovators as they tackle complexity and move science forward with greater speed and confidence.   Excited to see the real‑world impact this partnership can help deliver. https://lnkd.in/gsgmfWHv

Biomanufacturing is entering a new era: one defined by speed, integration, and the ability to turn scientific complexity into scalable impact. As biologics grow more advanced, manufacturers face mounting pressure to accelerate development, boost efficiency, and reduce resource intensity. A key driver of this shift: process intensification. Next‑generation upstream and downstream bioprocessing—enhanced by digital integration and real‑time analytics—is reshaping how therapies are made. These advances streamline workflows, shorten timelines, and increase consistency, helping teams scale innovation with greater certainty. Companies like Cytiva are helping enable the next era of scalable, flexible, and sustainable bioprocessing. 📘 Explore the brochure to learn what’s next for biomanufacturing.

Last week, we marked an important leadership milestone at Danaher as Matthew Gugino stepped into the role of Chief Financial Officer. With more than a decade of impact across Danaher, Matt has helped shape our financial strategy, guide portfolio evolution, and strengthen the operational rigor that enables us to accelerate science and technology from idea to impact. He'll continue to be a critical architect of our connected ecosystem—ensuring we invest, operate, and innovate in ways that advance our mission to improve human health. At the same time, we extend our deep gratitude to Matt McGrew, who has served as Danaher's CFO for the past seven years. His leadership helped build the Danaher we are today, and his legacy of disciplined growth and talent development will continue to serve us well. Please join us in congratulating Matt Gugino and celebrating Matt McGrew’s extraordinary contributions. https://lnkd.in/g8n6UDBx

What does it take to lead with both heart and impact? Meet Jessica Fletcher, Director of Client Technologies—a leader who didn’t just manage IT, but transformed it into a strategic force by putting people first. Over 14+ years at Pall Corporation, a Danaher life sciences business, Jessica’s journey has been anything but conventional. From embracing tough challenges and leading with intention, to learning from setbacks and mentoring the next generation, her story shows why empathy is the competitive advantage all leaders should care about. 💡 Whether you’re a seasoned leader or an emerging one, this story offers meaningful leadership lessons that resonate far beyond tech. Read the full journey and be inspired to lead with empathy. Link to the story in the comments. #danahercareers #speedoflife

Last week’s new guidance for the FDA’s Plausible Mechanism pathway is a critical first step toward accelerating rare disease drug development—but as Sadik Kassim notes, it’s only the beginning.   Foundational scientific investment helped early breakthroughs happen, but bridging the “last mile” of manufacturing continues to be a barrier. As Sadik shares, that’s where companies like Danaher and our businesses have stepped in to ensure promising therapies can move forward.   The new framework could empower more investigators to take on rare disease programs, but long‑term progress will require aligned incentives and sustained industry engagement. There’s real momentum building. And with thoughtful policy, collaboration, and industry engagement, we can help ensure that momentum leads to meaningful change for patients and families still waiting.   More in The Scientist: https://lnkd.in/grts2QHJ

Personalized gene editing is opening new possibilities for patients with ultra‑rare diseases—conditions that have historically lacked tailored therapeutic options. In a recent Forbes piece, Demaris Mills explores how rapidly evolving tools and scientific precision are helping make individualized treatments more feasible than ever. Scientific progress for rare disease patients won’t happen in isolation. Meaningful progress depends on partnerships that harness global scale, deep expertise, and a relentless drive to improve human health. At Danaher, we help enable the scientific ecosystem that turns promising concepts into reliable therapeutic options. As we observe #RareDiseaseDay, we recognize the urgent need—and tremendous potential—to expand access to life‑changing solutions for the millions of people affected worldwide. 🔗 Read the article: https://lnkd.in/e_AMqQAM

The most important health challenges of our time can’t be solved in isolation. At Danaher, our role is to bring the right technologies, expertise, and teams into sync, orchestrating the conditions where breakthroughs can move from idea to impact faster. Through collaborations like the Danaher Beacons—one of which resulted in the world’s first personalized genomic medicine—we work closely with academics, scientists, clinicians, and innovators across the globe to frame problems, uncover insights, and accelerate solutions. What makes this powerful isn’t any single capability, but the way our global network mobilizes to learn and improve continuously, and act with the urgency that scientific and patient needs demand. This is how we help turn possibility into real-world progress: not by working alone, but by bringing people and ideas together in ways that make meaningful breakthroughs possible. 💡 Learn more about Danaher Beacons: https://lnkd.in/gAYDu5hU

Danaher is honored to receive the 2026 ASGCT Catalyst Award, recognizing the collaboration behind the pioneering personalized gene‑editing therapy developed for Baby KJ. This is the first time the American Society of Gene & Cell Therapy has presented this honor to a corporation, underscoring the growing importance of cross‑sector partnerships in advancing personalized genomic medicine. As a connected ecosystem of life sciences and diagnostics innovators, Danaher works side‑by‑side with researchers and clinicians to co‑create solutions to the world’s toughest health challenges. We believe that collaboration, urgency, and scientific excellence can transform what’s possible in gene editing. We’re proud to be recognized alongside Dr. Rebecca Ahrens-Nicklas (Children's Hospital of Philadelphia), Dr. Kiran Musunuru (University of Pennsylvania School of Medicine), and Fyodor Urnov (University of California, Berkeley), and grateful to our partners Acuitas Therapeutics. Most importantly, at Danaher, Integrated DNA Technologies, and Aldevron, we honor Baby KJ and his family, whose journey reminds us why accelerating access to life‑changing therapies matters for every patient and every family. Learn more about the award: https://lnkd.in/eerVkmec